{"id":"NCT00106704","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","officialTitle":"A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-03","primaryCompletion":"2006-06","completion":"2007-01","firstPosted":"2005-03-30","resultsPosted":"2010-12-17","lastUpdate":"2015-07-01"},"enrollment":441,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Comparator: Sitagliptin","otherNames":[]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]},{"type":"DRUG","name":"Comparator: Pioglitazone","otherNames":[]}],"arms":[{"label":"Sitagliptin","type":"EXPERIMENTAL"},{"label":"Placebo/ Pioglitazone","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with Type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change From Baseline in A1C at Week 24","timeFrame":"Baseline and 24 Weeks","effectByArm":[{"arm":"Sitagliptin","deltaMin":-0.45,"sd":null},{"arm":"Placebo/ Pioglitazone","deltaMin":0.28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17593236"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":222},"commonTop":["Hypoglycaemia","Upper Respiratory Tract Infection","Nasopharyngitis","Headache","Urinary Tract Infection"]}}